BMJ Open Cost-utility of cytisine for smoking cessation over and above behavioural support in people with newly diagnosed pulmonary tuberculosis: an economic evaluation of a multicentre randomised controlled trial

Jinshuo Li ⁽¹⁾, ¹ Steve Parrott, ¹ Ada Keding, ¹ Omara Dogar, ^{1,2} Rhian Gabe, ³ Anna-Marie Marshall, ¹ Rumana Huque ⁽¹⁾, ^{4,5} Deepa Barua, ⁵ Razia Fatima, ⁶ Amina Khan, ⁷ Raana Zahid, ⁷ Sonia Mansoor, ⁸ Daniel Kotz, ^{2,9,10} Melanie Boeckmann ⁽¹⁾, ^{1,9} Helen Elsey ⁽¹⁾, ¹ Eva Kralikova, ^{11,12} Anne Readshaw, ¹ Aziz Sheikh, ² Kamran Siddiqi ⁽¹⁾, ^{1,13} on behalf of the TB & Tobacco Consortium

ABSTRACT

To cite: Li J, Parrott S, Keding A, *et al.* Cost-utility of cytisine for smoking cessation over and above behavioural support in people with newly diagnosed pulmonary tuberculosis: an economic evaluation of a multicentre randomised controlled trial. *BMJ Open* 2022;**12**:e049644. doi:10.1136/ bmjopen-2021-049644

Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (http://dx.doi.org/10.1136/ bmjopen-2021-049644).

Received 28 January 2021 Accepted 05 August 2022

Check for updates

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to Jinshuo Li; jinshuo.li@york.ac.uk **Objectives** To assess the cost-effectiveness of cytisine over and above brief behavioural support (BS) for smoking cessation among patients who are newly diagnosed with pulmonary tuberculosis (TB) in low-income and middleincome countries.

Design An incremental cost-utility analysis was undertaken alongside a 12-month, double-blind, two-arm, individually randomised controlled trial from a public/ voluntary healthcare sector perspective with the primary endpoint at 6 months post randomisation.

Setting Seventeen subdistrict hospitals in Bangladesh and 15 secondary care hospitals in Pakistan.

Participants Adults (aged \geq 18 years in Bangladesh and \geq 15 years in Pakistan) with pulmonary TB diagnosed within the last 4 weeks who smoked tobacco daily (n=2472).

Interventions Two brief BS sessions with a trained TB health worker were offered to all participants. Participants in the intervention arm (n=1239) were given cytisine (25-day course) while those in the control arm (n=1233) were given placebo. No significant difference was found between arms in 6-month abstinence.

Primary and secondary outcome measures Costs of cytisine and BS sessions were estimated based on research team records. TB treatment costs were estimated based on TB registry records. Additional smoking cessation and healthcare costs and EQ-5D-5L data were collected at baseline, 6-month and 12-month follow-ups. Costs were presented in purchasing power parity (PPP) adjusted US dollars (US\$). Quality-adjusted life years (QALYs) were derived from the EQ-5D-5L. Incremental total costs and incremental QALYs were estimated using regressions adjusting for respective baseline values and other baseline covariates. Uncertainty was assessed using bootstrapping. **Results** Mean total costs were PPP US\$57.74 (95% CI 49.40 to 83.36) higher in the cytisine arm than in the placebo arm while the mean QALYs were –0.001 (95% CI

STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ Large sample size and high follow-up rate ensures robustness of the conclusion.
- ⇒ Comprehensive patient-level data collection provides possibilities of further exploration or updating of the analyses.
- ⇒ Trial across two countries posed challenges to value both costs and quality-adjusted life years comparably.
- ⇒ Lack of up-to-date data sources of unit costs of healthcare services may affect the accuracy of the costs estimation.
- ⇒ Eagerness of local staff participating in the trial may affect the generalisability of the intervention delivery.

-0.004 to 0.002) lower over 6 months. The cytisine arm was dominated by the placebo arm.

Conclusions Cytisine *plus* BS for smoking cessation among patients with TB was not cost-effective compared with placebo *plus* BS.

Trial registration number ISRCTN43811467.

INTRODUCTION

In 2020, due to the impact of COVID-19 pandemic, the number of newly diagnosed tuberculosis (TB) case notifications saw a big drop from 2019 while the number of people who died from TB increased due to reduced access to services at global, regional and country levels.¹ Bangladesh (218 per 100 000 population) and Pakistan (259 per 100 000 population) are among the 16 countries that contributed most to the global shortfall

BMJ

of TB notifications yet they are still on the WHO highburden countries lists for TB and multidrug-resistant TB or rifampicin-resistant TB.^{1 2} Meanwhile, the 2020 estimates of current tobacco smoking rates were 18.5% in Bangladesh and 24.6% in Pakistan, with considerable imbalance between men and women.³ Previous evidence suggests that continued tobacco smoking among patients with TB is associated with unfavourable TB treatment outcomes.⁴ However, with the combined burden of TB and tobacco, support for smoking cessation for patients with TB is absent in both countries.⁵

TB treatment, lasting 6 months or longer, offers an opportunity for regular support for quitting smoking, if integrated properly. Newly diagnosed patients with TB who smoke might be more receptive to advice to quit due to their immediate health concerns.⁶ Due to limited resources, evidence-based approaches such as behavioural support (BS) and expensive pharmacotherapies for smoking cessation cannot be implemented in many low-income and middle-income countries (LMICs). We have previously developed, in collaboration with local teams in Bangladesh and Pakistan, a brief BS integrated with routine TB appointment for smoking cessation.⁷ In the present study, over-and-above the BS, we examined the effectiveness and cost-effectiveness of the relatively low cost pharmacotherapy cytisine for smoking cessation in patients with TB.⁸

We conducted a 12-month, two-arm, parallel, doubleblind, placebo-controlled, multicentre, individually randomised trial in Bangladesh and Pakistan to compare cytisine plus BS for smoking cessation (cytisine arm: n=1239) with placebo plus BS (placebo arm: n=1233) among patients with pulmonary TB who smoke daily.⁹ Biochemically-verified continuous abstinence at 6 months (primary endpoint) was 32.4% (401/1239) in the cytisine arm and 29.7% (366/1233) in the placebo arm (Relative Risk [RR]=1.09, 95% CI 0.97 to 1.23) and, at 12 months it was 24.9% (309/1239) and 22.3% (275/1233), respectively (RR=1.22, 95% CI 0.95 to 5.98), indicating no significant difference between arms in the primary outcome.¹⁰ This article reports a set of analyses to, respectively: (1) evaluate the cost-utility, from a public or voluntary healthcare sector perspective, of adding cytisine to BS for smoking cessation in patients with TB who smoke; and (2) assess the financial burden in relation to tobacco use and healthcare from participants and their families' perspective, and estimate productivity loss using lost income.

METHODS

Design

An incremental cost-utility analysis was conducted alongside the randomised controlled trial (RCT) described above and elsewhere.^{9 10} The scheduled follow-ups were at 6 and 12 months post randomisation, with 6 months as the primary endpoint. Neither participants nor TB health workers were aware of participants' arm allocation. Allocation was not revealed to health economists until database lock. Detailed information on procedures was provided in the study protocol.⁹

Participants

Adults (aged ≥ 18 in Bangladesh and ≥ 15 in Pakistan) with pulmonary TB diagnosed within the last 4 weeks who smoked tobacco on a daily basis and were interested in quitting were eligible.⁹ We excluded those who were diagnosed with TB complications (retreatment or any drug resistance), extrapulmonary TB, receiving streptomycin and/or para-aminosalicylic acid, using any pharmacotherapy for tobacco dependence, pregnant or planning to become pregnant, lactating or suffering from schizophrenia or known to be diagnosed with epilepsy. Those who had myocardial infarction, stroke or an attack of severe angina within the previous 2 weeks, uncontrolled high blood pressure despite being on medication or severe renal impairment (requiring dialysis) were also excluded.

Between June 2017 and April 2018, 1527 participants from 17 subdistrict hospitals in Bangladesh and 945 participants from 15 secondary care hospitals in Pakistan were randomised to the cytisine arm (n=1239) and the placebo arm (n=1233). The mean age was 42.5 (SD 14.3) years in the cytisine arm and 42.4 (SD 14.2) years in the placebo arm. Men made up 99% of each arm (1227 in the cytisine arm and 1221 in the placebo arm). By 6 months follow-up, 70 participants died (36 in the cytisine arm and 34 in the placebo arm). A further 21 participants died after 6 months (13 in the cytisine arm and 8 in the placebo arm).

Intervention and comparator

Participants in the cytisine (intervention) arm were provided with cytisine (Desmoxan, Aflofarm, Pabianice, Poland) according to its standard regimen: 38 capsules on day 0 and another 62 capsules on day 5 (preset quit date), totalling 100 capsules over a 25-day course. The trial medication was in the form of 1.5 mg hard capsules for oral administration.^{9 10} Participants in the placebo (comparator) arm were given placebo capsules with identical appearance on the same dispensing schedule. In addition, participants in both arms were offered brief BS for smoking cessation delivered by trained TB health workers, accompanied with a leaflet containing information on tobacco use and its interactions with TB for each participant. The BS was designed to be two face-to-face sessions on days 0 (10 minutes) and 5 (5 minutes). Therefore, the intervention consisted of cytisine plus BS while the comparator was placebo plus BS.

Measures

All monetary outcomes were collected or valued in local currencies and inflated to their respective 2018 values,¹¹ where necessary, and converted to purchasing power parity adjusted US dollars (PPP US\$) using the World Bank exchange rate in the same year (1 PPP US\$=30.9

Bangladeshi Taka=29.3 Pakistani Rupees).¹² PPP US\$ accounts for the price and income difference between the two countries so that the monetary outcomes could be pooled together. Results of costs were presented in PPP US\$ 2018 price.

Costs

Intervention costs

Intervention costs included costs of training and delivery (see online supplemental file 1). TB health workers were trained in brief BS for smoking cessation in a 2-day programme. The costs of training were estimated by the research team to be PPP US\$14 183 in Bangladesh and PPP US\$12 837 in Pakistan. Since all participants were scheduled to receive BS, the training cost was allocated to each participant evenly.

The uptake of BS was recorded on the case report form (CRF) on day 0. Staff costs for BS were estimated by multiplying the duration by the hourly wage rate. The cost of BS for the first and second session was PPP US\$0.52 and PPP US\$0.26 in Bangladesh and PPP US\$0.75 and PPP US\$0.38 in Pakistan. For those whose CRF showed not taking up BS, the cost of BS delivery was considered null. For those who accepted BS, the cost of the first session was applied and the cost of the second session was added provided they attended the follow-up on day 5. The smoking cessation information leaflet offered to each participant costed PPP US\$0.16 in Bangladesh and PPP US\$1.71 in Pakistan.

The manufacturer provided the distributor price as 72.63 Polish złoty for 100 capsule pack (PPP US\$42.27 in Bangladesh and PPP US\$65.09 in Pakistan). By dispensing schedule, the medication dispensed on day 0 costed PPP US\$16.05 in Bangladesh and PPP US\$24.74 in Pakistan, and on day 5 it costed PPP US\$26.21 in Bangladesh and PPP US\$40.34 in Pakistan. The placebo capsules were assumed to incur no cost. All participants had at least the first dispense and those who missed follow-up on day 5 were assumed not to receive the second dispense.

Costs of TB treatment, additional smoking cessation help and general healthcare services

Table 1 presents the unit costs of TB treatment by phase, additional smoking cessation services and general healthcare services estimated based on secondary sources and some assumptions and converted to PPP US\$ 2018^{12–22} (for detailed methods of estimation see online supplemental file 1). TB treatment progression was estimated according to the TB registry card. The quantities of services use were collected by self-report at baseline, 6-month and 12-month follow-ups (see online supplemental file 2 for CRF).

Out-of-pocket payments and productivity loss

Participants reported any spending in monetary form related to TB treatment, smoking cessation products and general healthcare services use, including travel, on CRFs at baseline, 6-month and 12-month follow-ups.

CRFs also collected participants' time spent in TB clinics and doctor visits, including travel and waiting time, and if and how many times they were accompanied by a friend or relative. The productivity loss of a companion was estimated by multiplying the overall time spent by the companion by the societal average hourly wage in the country.^{20 21} We assumed that all companions were employed. Participants' productivity loss was estimated based on their self-reported duration of sick leave from work. Participants' hourly wages were extracted from secondary sources based on their occupation category and gender,^{20'21} with those reported in open question reclassified according to the International Standard Classification of Occupations (online supplemental file 3, table S1).²³ Those who were unemployed, retired, students or home makers were assumed to incur no productivity loss in the case of sick leave.

Quality-adjusted life years

The EQ-5D-5L developed by the EuroQol Group was used to measure health-related quality of life, 24 at baseline,

	Unit cost (PPP US\$, 2017/2018)			
Cost items	Bangladesh	Pakistan	Sources	
TB treatment				
First-line treatment, intensive phase, including drugs	54.21 per month	108.40 per month	12–15	
First-line treatment, continuation phase, including drugs	31.62 per month	63.24 per month		
Smoking cessation services				
Help or advice from public/government clinic/hospital	0.68 per use	0.89 per use	12 19–21	
Group or single counselling session at public/voluntary clinic	0.94 per session	1.26 per session	12 18 20 21	
General healthcare services				
Doctor visit	4.60 per visit	6.83 per visit	11 12 22	
Hospital inpatient	19.06 per bed-day	33.14 per bed-day	11 12 22	

6-month and 12-month follow-ups, as part of the CRFs. The EQ-5D-5L consists of a descriptive system of five domains (mobility, self-care, usual activities, pain/discomfort and anxiety/depression), and a Visual Analogue Scale (VAS) valuing the overall health on the day. The VAS score ranges from 0 (death) to 100 (perfect health). Each domain of the descriptive system has five levels of capacity, ranging from having no problem to having severe problems. A complete descriptive system could be converted to a utility value using an appropriate tariff.

In the absence of country-specific valuation sets for Bangladesh and Pakistan, we used the valuation set of Zimbabwe based on crosswalk function to calculate utility,²⁵ as its gross domestic product per capita in PPP US\$ (2381.22) was the closest to that of the two countries of interest (Bangladesh: 4598.39 and Pakistan: 5714.03) at the time of the analysis.²⁶ Quality-adjusted life years (QALYs) were derived using the area under the curve approach.²⁷

Analyses

All analyses were performed using Stata/SE V.16.0.

Missing data

For the baseline covariates, missing values were imputed by the mean of the variable in the pooled sample in the same country. This was the information that was unrelated to the intervention and the randomisation functioned to balance the two arms.²⁸ The missing values in the follow-up variables were handled using multiple imputation method, following Rubin's rule and assuming missing at random (MAR),²⁹ unless it was due to death. Missing values due to death were replaced with zero or not applicable (n/a) depending on the nature of variable. An imputation model was developed to include all the variables necessary for the analysis and the number of imputations was set as approximately the highest percentage figure of missing data.³⁰ The imputation was performed by trial arms and on condition of being alive.

Primary analysis

The primary analysis was an incremental cost-utility analysis over 6 months post randomisation from a public or voluntary healthcare sector perspective. This included service providers that were classified as government, non-profit organisations and charitable organisations. It was undertaken on an intention-to-treat basis, including all randomised participants in the arms to which they were allocated.

Total costs at 6 months consisted of intervention costs, TB treatment costs, additional public/voluntary smoking cessation costs and public/voluntary healthcare services costs in the 6 months post randomisation. Mean total costs and mean QALYs were estimated for each arm and no discounting was applied for the 6 months period. Incremental mean total costs and incremental mean QALYs were estimated by a mixed effect generalised linear regression model, adjusting for their respective baseline values (total costs in the 6 months before randomisation for total costs; baseline EQ-5D-5L utility for QALYs), age, gender and country, with study site as random-effects. An incremental cost-effectiveness ratio (ICER) was calculated by dividing the incremental mean total costs by the incremental mean QALYs.

Since there are no official willingness-to-pay (WTP) thresholds in either Bangladesh or Pakistan, the estimated WTPs for Bangladesh and Pakistan based on income elasticity of value of health, inflated to 2018 (maximum WTP: Bangladesh: PPP US\$1473 per QALY gained and Pakistan: PPP US\$2431 per QALY gained), were used to compare with the ICERs, if applicable.³¹

Because neither costs nor QALYs were normally distributed, we used a non-parametric bootstrap technique to assess the uncertainty, generating 5000 replicate samples. The results were used to construct 95% CIs of the incremental costs and QALYs. They were then plotted on a cost-effectiveness plane (CEP) to demonstrate the uncertainty surrounding the ICER. Cost-effectiveness acceptability curves (CEACs) were constructed from these bootstrapped replicates by converting ICER to net monetary benefit.³²

A separate cost-effectiveness analysis using smoking abstinence rate at 6 months follow-up as effect measure was planned but not undertaken because no statistically significant difference was found between arms for this outcome measure per prespecified effect size.¹⁰ Given that it is not clinically effective, it could not be cost-effective using this measure.

Sensitivity analyses

We undertook a complete case analysis (CCA) on the participants who had complete outcome and covariates data to provide a comparison with the primary analysis based on imputed data. We examined the MAR assumption that supports the multiple imputation by undertaking sensitivity analyses based on missing not at random assumptions using a practical approximation to the pattern mixture model:²⁸ (1) imputed total costs were increased by 10%, 20% and 30% and (2) imputed QALYs were reduced by between 10%, 20% and 30%. To assess the impact of choice of EQ-5D-5L tariff, we took the validated population valuation sets from countries in the southeast Asia area (ie, Indonesia, Malaysia, Thailand) and the crosswalk functions of the UK and Thailand to calculate utility for comparison.^{25 33–35}

Secondary analyses

The first secondary analysis followed the methods of the primary analysis, extending time horizon to a 12-month period. No discounting was applied as this was not longer than 1 year. We summarised participants' out-of-pocket payments (OOPs) in relation to TB treatment, smoking cessation and healthcare services by arm, at both 6 and 12 months. Productivity losses of participants' sick leave and their companion to treatment and money spent on any forms of tobacco were also summarised. We have also repeated the analysis by countries following the same methods of the primary analysis above.

Patient and public involvement

Patient groups were consulted on the intervention materials for their lucidness during the intervention development stage. No other patient and public involvement occurred in the study process.

RESULTS

Missing data

The results of observed cases are presented in online supplemental file 1. The proportion of missing data at baseline was low (online supplemental file 3, table S2). The greatest percentage of missing data level was 12% of participants' OOPs for smoking cessation at 6 months follow-up, followed by the same variable at 12 months (10%).

Although the level of missingness did not differentiate between arms, most of the missingness of follow-up variables was significantly associated with country. The missingness of OOP for smoking cessation in months 1–6 was weakly associated with participants' age (online supplemental file 3, table S3). Using a logistic regression for missingness of follow-up variables on their respective previously observed values (eg, missingness of costs at 6 months on costs at baseline), most results were not statistically significant (p>0.05), with few exceptions. These results supported the MAR assumption. The imputation number was set to 15.

Primary analysis

The mean costs of smoking cessation and healthcare services in the 6 months before baseline were PPP US\$10.36 (SE PPP US\$1.74) in the cytisine arm and PPP US\$8.52 (SE PPP US\$1.41) in the placebo arm. The mean total costs over the 6 months post randomisation were PPP US\$401.52 (SE PPP US\$8.91) in the cytisine arm and PPP US\$334.73 (SE PPP US\$5.85) in the placebo arm (table 2). Costs of additional smoking cessation were negligible in both arms. The mean costs of hospital stay in the cytisine arm were almost twice those in the placebo arm. The incremental total costs were PPP US\$57.74 (95% CI PPP US\$49.40 to PPP US\$83.36). The mean QALYs were 0.395 (SE 0.002) in the cytisine arm and 0.398 (SE 0.002) in the placebo arm. The incremental QALYs were -0.001 (95% CI -0.004 to 0.002). The majority (78.1%, 3905/5000) of the bootstrapped replicates fell in the north-west quadrant of CEP, indicating a more costly, but less effective intervention (figure 1, left). The CEAC was not presented as it was a straight line at 0% probability of cost-effectiveness at the WTP range from PPP US\$0 to PPP US\$1473 per QALY gained for Bangladesh or PPP US\$2431 per QALY gained for Pakistan.

Sensitivity analyses

The CCA was performed on 1122 participants in the cytisine arm and 1116 participants in the placebo arm. The results were similar to that of the primary analysis (table 2, right). The overall majority (91%, 4550/5000) of the bootstrapped replicates fell in the north-west

	Primary analysis	;	Complete case a	nplete case analysis	
	Cytisine (n=1239)	Placebo (n=1233)	Cytisine (n=1122)	Placebo (n=1116)	
Costs (PPP US\$)	Mean (SE)		Mean (SD)		
Intervention	60.65 (0.41)	12.37 (0.08)	61.25 (13.83)	12.15 (2.69)	
TB treatment	305.15 (3.36)	301.83 (3.36)	306.53 (109.96)	301.36 (108.09)	
Doctor visit	3.36 (0.37)	3.10 (0.31)	3.47 (13.17)	3.14 (10.58)	
Hospital stay	31.91 (7.73)	16.98 (4.41)	33.08 (275.18)	17.26 (151.58)	
Smoking cessation	0.46 (0.03)	0.45 (0.03)	0.49 (1.19)	0.49 (1.13)	
Overall total for 6 months	401.52 (8.91)	334.73 (5.85)	404.82 (311.99)	334.39 (196.52)	
PPP US\$, mean (95% CI)					
Adjusted incremental costs	57.74 (49.40 to 8	3.36)	59.49 (51.95 to 89	.30)	
	Mean (SE)		Mean (SD)		
QALYs over 6 months	0.395 (0.002)	0.398 (0.002)	0.401 (0.041)	0.403 (0.039)	
QALYs, mean (95% CI)					
Adjusted incremental QALYs	-0.001 (-0.004 to	0.002)	-0.001 (-0.003 to	0.000)	
ICER	-	Cytisine dominated by placebo (uncertainty, see figure 1 left)		Cytisine dominated by placebo (uncertainty, see figure 1 right)	

ICER, incremental cost-effectiveness ratio; PPP, purchasing power parity; QALYs, quality-adjusted life years; TB, tuberculosis; US\$, US dollars.




Figure 1 Cost-effectiveness plane of primary and complete case analyses at 6 months post randomisation (dashed purple line as WTP for Pakistan and dotted green line as WTP for Bangladesh). PPP, purchasing power parity; QALY, quality-adjusted life year; US\$, US dollars; WTP, willingness-to-pay.

quadrant of CEP (figure 1, right), indicating a more costly, but less effective intervention. This was consistent with the primary analysis.

Under scenario (1), when the imputed costs were increased by 10%, 20% and 30%, the incremental costs became PPP US\$58.32, PPP US\$58.91 and PPP US\$59.51, respectively. Under scenario (2), when the imputed QALYs were reduced by 10%, 20% and 30%, the incremental QALYs were -0.001 to -0.001 and -0.000, respectively. None differed far from the primary analysis results.

Using tariffs derived in different countries or with different approaches, the incremental QALYs between arms varied (figure 2), but the level of difference was not prominent and the general pattern between arms remained the same.

Secondary analyses

The addition of the costs in months 7–12 increased the mean total costs over 12 months to PPP US\$408.31 (SE PPP US\$10.03) in the cytisine arm and PPP US\$341.83 (SE PPP US\$6.50) in the placebo arm. The incremental costs were PPP US\$56.72 (95% CI PPP US\$46.58 to PPP




Figure 2 Comparison of adjusted incremental QALYs over 6 months post randomisation derived from different methods. QALYs, quality-adjusted life years.

US\$86.00), similar to those over the 6 months post randomisation. By contrast, as the time horizon doubled, the QALYs became almost twice as high as over the 6-month period, which led to a larger difference in mean QALYs between arms. The mean QALYs were 0.808 (SE 0.004) in the cytisine arm and 0.814 (SE 0.004) in the placebo arm. The incremental QALYs were -0.004 (95% CI -0.013 to 0.005). The cytisine arm remained dominated by the placebo arm, with 77% (4007/5000) of the bootstrapped estimates indicating a less effective, but more costly intervention.

Over the 12 months follow-up period, the mean OOPs were PPP US\$108.91 (SE PPP US\$19.79) in the cytisine arm and PPP US\$81.74 (SE PPP US\$11.73) in the placebo arm. The main cost driver was OOP for doctor visits in both arms, while in the cytisine arm participants also spent more on hospital stays (table 3). This pattern was consistent with costs from the public or voluntary healthcare sector's perspective. Productivity losses mostly occurred before and during TB treatment period and decreased considerably in the last 6 months of the trial. The OOP for tobacco products dropped after randomisation in both arms but remained stable throughout the 12 months period post randomisation, which was consistent with the quit rates observed in both arms.

The cost-utility analyses by country did not lead to different conclusions from the primary analysis. In Bangladesh, the adjusted incremental costs were PPP US\$37.06 (95% CI PPP US\$28.12 to PPP US\$43.85) and the adjusted incremental QALYs were -0.003 (95% CI -0.006 to 0.000) with the cytisine arm remaining dominated by the placebo arm. In Pakistan, the adjusted incremental costs were PPP US\$108.46 (95% CI PPP US\$69.69 to PPP US\$157.88) and the adjusted incremental QALYs were 0.001 (95% CI -0.004 to 0.008). The ICER was calculated at PPP US\$108 464 per QALY, which was much higher than the adopted maximum WTP threshold PPP US\$2431 per QALY. The cost-effectiveness plane also shows that cytisine plus BS had 0% of being cost-effective within the adopted WTP threshold range in both countries (online supplemental file 1). However, the breakdown of total costs by country indicated that the higher mean costs of hospital stay in the cytisine arm were mostly contributed by the cytisine arm in Pakistan (PPP US\$78.12 vs PPP US\$32.70 in placebo arm). While in Bangladesh, the mean costs of hospital stay were PPP US\$3.07 (SE PPP US\$1.62) in the cytisine arm and PPP US\$7.34 (SE PPP US\$3.82) in the placebo arm. A further examination also showed possible outliers in the cytisine arm in Pakistan. The improvement in utility from baseline to 6 months was more manifest in Bangladesh than in Pakistan, regardless of the arms. Detailed results are presented in online supplemental file 1.

DISCUSSION

The intervention cost was PPP US\$60.65 (SE PPP US\$0.41) per participant in the cytisine arm and PPP US\$12.37 (SE

 Table 3
 Mean out-of-pocket payments for health-related services, productivity loss and payments for tobacco products at three time points, by arm

PPP US\$ Mean (SE)	Cytisine (n=1239)	Placebo (n=1233)
Six months before baseline		
OOPs for health-related services	84.90 (7.91)	86.70 (6.80)
TB treatment	15.60 (1.69)	19.71 (3.42)
Doctor visit	62.29 (6.90)	63.96 (5.67)
Hospital stay	6.97 (2.87)	3.02 (0.80)
Smoking cessation	0.04 (0.02)	0.01 (0.01)
Productivity loss	34.01 (2.14)	30.41 (1.81)
OOPs for tobacco products	1.79 (0.14)	1.64 (0.07)
Months 1–6		
OOPs for health-related services	69.70 (10.62)	51.08 (9.32)
TB treatment	22.16 (2.51)	16.24 (1.30)
Doctor visit	29.49 (7.52)	22.65 (6.08)
Hospital stay	17.65 (5.90)	11.89 (6.53)
Smoking cessation	0.40 (0.09)	0.30 (0.06)
Productivity loss	48.83 (3.00)	43.52 (3.14)
OOPs for tobacco products	0.51 (0.03)	0.50 (0.03)
Months 7–12		
OOPs for health-related services	39.21 (16.11)	30.66 (6.72)
TB treatment	5.03 (1.43)	4.55 (0.92)
Doctor visit	13.05 (2.41)	20.42 (5.22)
Hospital stay	21.08 (15.80)	5.64 (2.89)
Smoking cessation	0.04 (0.02)	0.05 (0.02)
Productivity loss	6.06 (0.58)	8.32 (0.97)
OOPs for tobacco products	0.61 (0.03)	0.58 (0.02)

OOPs, out-of-pocket payments; PPP, purchasing power parity; TB, tuberculosis; US\$, US dollars.

PPP US\$0.08) per participant in the placebo arm. The difference was mainly attributed to cytisine medication. The incremental total costs at 6 months post randomisation were estimated at PPP US\$57.74 (95% CI PPP US\$49.40 to PPP US\$83.36) while the incremental QALYs were estimated at -0.001 (95% CI -0.004 to 0.002). These results indicated that adding cytisine to brief BS for quitting smoking was unlikely to be cost-effective. The sensitivity analyses confirmed the robustness of this conclusion. Extending the time horizon to 12 months did not change the conclusion.

While the observed quit rates were not statistically significantly different between arms,¹⁰ participants' OOP for tobacco products on average dropped by nearly twothirds after randomisation indicating a reduction of tobacco consumption. The higher than expected productivity loss, OOPs for doctor visits and TB treatment before baseline might be because participants had experienced some symptoms and sought medical attention before TB was diagnosed. It was unclear, however, why participants in the cytisine arm reported more and longer hospital stays than the placebo arm in Pakistan. Our process evaluation study found some difference in intervention delivery between countries,^{36,37} but we did not find evidence of differential TB treatment outcomes between trial arms in Pakistan,¹⁰ and the same situation was not observed in Bangladesh. This might indicate a potential country-related contextual reason rather than the effect of the intervention or occurrence by chance. Subgroup analyses by patient characteristics and deterministic sensitivity analysis of key parameters were not planned because of the lack of clear underlying hypotheses. Moreover, limited by the research capacity, the sample size of the subgroups was likely to be insufficient to produce valid results.

The strength of the study stems from the large sample size and high follow-up rates. Despite limitations of published data availability, patient level measures were collected using a comprehensive questionnaire to enable a full cost-utility analysis to be undertaken. However, several limitations could potentially affect the results. First, our estimated costs could be an underestimation. We observed that some health workers discussed smoking cessation during several routine TB consultations and some research assistants delivered the study drug to participants if they had missed day 5 follow-up. TB treatment costs were estimated based on simplified scenarios. Intensive treatments in the case of deterioration, death or retreatment were not considered. Costs of general medication were not included because our unit costs data source for healthcare services did not include them. However, this should not bias the results towards either arm. Second, the data source of unit costs of healthcare services was last updated in 2010. Certain changes may not be accounted for by simple inflation. While an up-to-date data source was not available at the time of analysis, the results could be updated when it becomes available as the service use was collected in quantities. Third, productivity loss in the case of death was considered zero but if a lifetime observation or modelling were undertaken productivity loss due to premature death should be included. Given the large sample size and few deaths that occurred, this was unlikely to affect the conclusions. Last but not least, our sample consisted mostly of men. This reflected the low daily tobacco smoking rate among women in both countries at the time of the trial (0.8% in Bangladesh and 2.0% in Pakistan).⁵ There may therefore be challenges in making inferences to women in these countries.

To our knowledge, this is the first cost-utility study of cytisine as a smoking cessation aid alongside an RCT and one of few for smoking cessation intervention in LMICs. A systematic review published in 2019 identified eight placebo-controlled trials and one non-inferiority trial (using nicotine replacement therapies) that used cytisine for smoking cessation, all of which were among smokers in general population and only one was conducted in LMICs.⁸ Although cytisine has been identified as affordable globally,³⁸ its cost-effectiveness in smoking cessation was based on modelled economic evaluation not empirical evidence.³⁹ Our study illustrated that though less costly than other cessation aids, cytisine did not show sufficient effects to be considered cost-effective.

Our findings do not support the cost-effectiveness of adding cytisine to BS for smokers who are newly diagnosed with pulmonary TB. In the absence of more effective smoking cessation aid, future studies should explore the cost-effectiveness of non-pharmacological cessation interventions in LMICs, given the relatively lower costs of labour and possible impact of smoking-related comorbidities on quality of life in the TB population.

Author affiliations

¹Department of Health Sciences, University of York, York, North Yorkshire, UK

²Usher Institute, The University of Edinburgh, Edinburgh, UK

³Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK

⁴Department of Economics, University of Dhaka, Dhaka, Bangladesh

⁵ARK Foundation, Dhaka, Bangladesh

⁶TB/HIV and Malaria Common Management Unit, Global Fund Grant, Islamabad, Pakistan

⁷The Initiative, Islamabad, Pakistan

⁸Institute of Psychiatry, Rawalpindi Medical University, Rawalpindi, Pakistan ⁹Institute of General Practice, Addiction Research and Clinical Epidemiology Unit, Medical Faculty, Heinrich-Heine-Universität Düsseldorf, Dusseldorf, Nordrhein-Westfalen, Germany

¹⁰Department of Family Medicine, CAPHRI School for Public Health and Primary Care, Maastricht University, Maastricht, The Netherlands

¹¹Institute of Hygiene and Epidemiology, First Faculty of Medicine, Charles University and the General University Hospital in Prague, Praha, Czech Republic

¹²3rd Medical Department, First Faculty of Medicine, Charles University and General University Hospital in Prague, Praha, Czech Republic

¹³Hull York Medical School, University of York, York, UK

 $\ensuremath{\mathsf{Twitter}}$ Omara Dogar @Tobacco & Lung Health and Melanie Boeckmann @m_boeckmann

Collaborators TB & Tobacco Consortium (in addition to those in the main author list) Shilpi Swami, Samina Huque, Ejaz Qadeer, Maryam Noor, Salman Sohail, Jiban Karki, Iveta Nohavová, Kamila Zvolská, Alexandra Pánková, Sushil Baral (PI), Shophika Regmi, Prabin Shrestha, Basant Joshi, Ramesh Pathak.

Contributors JL conducted the cost-effectiveness analysis and drafted the manuscript under the supervision of SP. SP also contributed to the analysis design. AKe contributed to data management and statistical analysis, including some clinical measures used in this manuscript. OD and RG contributed to study design, conduct and interpretation of findings. AR and A-MM managed the study and contributed to interpretation of findings. RH, DB, RF, AK, RZ and SM conducted the study in Bangladesh/Pakistan, collected and managed the data in countries and provided critical inputs to data analysis and interpretation. DK, EK, MB and HE provided insights to study design on aspects of behavioural support implementation, evaluation of its delivery and interpretation of findings. AS provided critical oversight to study design, trial conduct, interpretation of findings and discussion. KS conceptualised the study, contributed to the study design, conduct and interpretation of findings. All authors provided critical revisions and approved the final manuscript. JL acts as guarantor and accepts full responsibility of the overall content.

Funding This work was supported by the European Union's Horizon 2020 research and innovation programme, under Grant Agreement No. 680995.

Competing interests KS received a research grant from Pfizer (2015–2017) to study the effects of varenicline (a smoking cessation medication) on waterpipe smoking cessation. DK received an unrestricted grant from Pfizer in 2009 for an investigator-initiated trial on the effectiveness of practice nurse counselling and varenicline for smoking cessation in primary care (Dutch Trial Register NTR3067; DOI: 10.1111/add.13927). The medication for the trial were provided by Aflofarm free of charge. AS is supported by Health Data Research UK's BREATHE Hub.

Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication Not applicable.

Ethics approval The Health Sciences Research Governance Committee (HSRGC), University of York, UK: HSRGC/2016/144/B; The National Bioethics Committee, Pakistan Medical Research Council: no. 4–87/16/NBC-200 Part-B/RDC/4197; The National Research Ethics Committee, Bangladesh Medical Research Council: BMRC/ NREC/2016–2019/1475. Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given,

and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

ORCID iDs

Jinshuo Li http://orcid.org/0000-0003-1496-7450 Rumana Huque http://orcid.org/0000-0002-7616-9596 Melanie Boeckmann http://orcid.org/0000-0001-5909-5508 Helen Elsey http://orcid.org/0000-0003-4724-0581 Kamran Siddiqi http://orcid.org/0000-0003-1529-7778

REFERENCES

- World Health Organization. Global tuberculosis report 2021. Geneva, 2021. Available: https://www.who.int/publications/i/item/ 9789240037021
- 2 World Health Organization. TB country, regional and global profiles [Internet], 2021. Available: https://worldhealthorg.shinyapps.io/tb_ profiles/ [Accessed 01 Dec 2021].
- 3 World Health Organization. WHO global report on trends in prevalence of tobacco use 2000-2025. Geneva, 2021. Available: https://www.who.int/publications/i/item/9789240039322
- 4 Chaves Torres NM, Quijano Rodríguez JJ, Porras Andrade PS, et al. Factors predictive of the success of tuberculosis treatment: a systematic review with meta-analysis. *PLoS One* 2019;14:e0226507.
- 5 World Health Organization (WHO). Tobacco control profiles countries, territories, and areas: Tobacco Free Initiative, 2019. Available: https://www.who.int/tobacco/surveillance/policy/country_ profile/en/#P [Accessed 06 Jul 2020].
- 6 Lawson PJ, Flocke SA. Teachable moments for health behavior change: a concept analysis. *Patient Educ Couns* 2009;76:25–30.
- 7 Elsey H, Warsi S. Report of TB and Tobacco Project WP1: tobacco cessation intervention development [Internet],]2017. Available: https://tbandtobacco.org/wp-content/uploads/sites/26/2019/05/ WP1-Report-of-intervention-development.pdf [Accessed 01 Dec 2021].
- 8 Tutka P, Vinnikov D, Courtney RJ, *et al.* Cytisine for nicotine addiction treatment: a review of pharmacology, therapeutics and an update of clinical trial evidence for smoking cessation. *Addiction* 2019;114:1951–69.
- 9 Dogar O, Barua D, Boeckmann M, *et al*. The safety, effectiveness and cost-effectiveness of cytisine in achieving six-month continuous smoking abstinence in tuberculosis patients-protocol for a double-blind, placebo-controlled randomized trial. *Addiction* 2018;113:1716–26.
- 10 Dogar O, Keding A, Gabe R, et al. Cytisine for smoking cessation in patients with tuberculosis: a multicentre, randomised, doubleblind, placebo-controlled phase 3 trial. Lancet Glob Health 2020;8:e1408–17.
- 11 International Monetary Fund (IMF). Prices, Consumer Price Index, All items, Index [Internet], 2019. Available: http://data.imf.org/regular. aspx?key=61545861
- 12 DataBank World Development Indicators [Internet], 2019. Available: https://databank.worldbank.org/reports.aspx?source=2&series=PA. NUS.PPP&country=PAK# [Accessed 26 Jun 2019].
- 13 WHO. Global Tuberculosis report 2018 TB data [Internet, 2018. Available: https://www.who.int/tb/country/data/download/en/
- 14 Gomez GB, Dowdy DW, Bastos ML, *et al*. Cost and costeffectiveness of tuberculosis treatment shortening: a model-based analysis. *BMC Infect Dis* 2016;16:726.
- 15 International Monetary Fund (IMF). National Currency per U.S. Dollar, period average [Internet], 2019. Available: http://data.imf.org/regular. aspx?key=61545862 [Accessed 08 May 2019].
- 16 World Health Organization. Tobacco control country profile Pakistan. initiative TF, 2017. Available: https://www.who.int/tobacco/ surveillance/policy/country_profile/pak.pdf?ua=1
- 17 World Health Organization. Tobacco control country profile Bangladesh. initiative TF, 2017. Available: https://www.who.int/ tobacco/surveillance/policy/country_profile/bgd.pdf?ua=1
- 18 National Institute for Health and Care Excellence. Putting NICE guidance into practice Resource impact report: Stop smoking

interventions and services (NG92), 2018. Available: https://www. nice.org.uk/guidance/ng92/resources/resource-impact-report-pdf-4788823645

- 19 Curtis LA, Burns A. Unit costs of health and social care 2018. project report. Kent: University of Kent, 2018. https://kar.kent.ac.uk/70995/1/ Unit%20Costs%202018%20-%20FINAL%20with%20bookmarks% 20and%20covers.pdf
- 20 Bangladesh Bureau of Statistics. Report on labour force survey (LFS) 2016-17. statistics, informatics division MOP, 2018. Available: https://www.ilo.org/surveydata/index.php/catalog/2047/download/ 16818
- 21 Ministry of Statistics GoP. Pakistan Bureau of statistics. labour force survey 2017-18, 2018. Available: http://www.pbs.gov.pk/sites/ default/files//Labour%20Force/publications/lfs2017_18/Annual% 20Report%20of%20LFS%202017-18.pdf
- 22 Economic Analysis Evaluation Team. Country-specific inpatient and outpatient estimates in 2010 currency. World health organisation, department of health systems G, financing, 2010. Available: https:// www.who.int/choice/cost-effectiveness/inputs/country_inpatient_ outpatient_2010.pdf?ua=1
- 23 International Labour Office. International standard classification of occupations: ISCO-08. Geneva: ILO, 2012.
- 24 EuroQol Research Foundation. EQ-5D-5L user guide: basic information on how to use the EQ-5D-5L instrument (version 3.0), 2019. Available: https://euroqol.org/publications/user-guides/
- 25 van Hout B, Janssen MF, Feng Y-S, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health 2012;15:708–15.
- 26 International Monetary Fund (IMF). IMF DataMapper GDP per capita, current prices (Purchasing power parity; international dollars per capita) [Internet], 2018. Available: https://www.imf.org/external/ datamapper/PPPPC@WEO/BGD/PAK/ZWE/GBR/THA/MYS/IDN/ SEQ?year=2018
- 27 Richardson G, Manca A. Calculation of quality adjusted life years in the published literature: a review of methodology and transparency. *Health Econ* 2004;13:1203–10.
- 28 Faria R, Gomes M, Epstein D, *et al.* A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials. *Pharmacoeconomics* 2014;32:1157–70.
- 29 Rubin DB. Statistical matching using file concatenation with adjusted weights and multiple Imputations. *J Bus Econ Stat* 1986;4:87–94.
- 30 White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. *Stat Med* 2011;30:377–99.
- 31 Woods B, Revill P, Sculpher M, et al. Country-Level costeffectiveness thresholds: initial estimates and the need for further research. *Value Health* 2016;19:929–35.
- 32 Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. *Health Econ* 2001;10:779–87.
- 33 Pattanaphesaj J, Thavorncharoensap M, Ramos-Goñi JM, et al. The EQ-5D-5L valuation study in Thailand. Expert Rev Pharmacoecon Outcomes Res 2018;18:551–8.
- 34 Purba FD, Hunfeld JAM, Iskandarsyah A, et al. The Indonesian EQ-5D-5L value set. *Pharmacoeconomics* 2017;35:1153–65.
- 35 Shafie AA, Vasan Thakumar A, Lim CJ, *et al*. EQ-5D-5L valuation for the Malaysian population. *Pharmacoeconomics* 2019;37:715–25.
- 36 Boeckmann M, Warsi S, Noor M, *et al.* Health worker and patient views on implementation of smoking cessation in routine tuberculosis care. *NPJ Prim Care Respir Med* 2019;29:34.
- 37 Boeckmann M, Dogar O, Saeed S, et al. Measuring fidelity to delivery of a new smoking cessation intervention integrated into routine tuberculosis care in Pakistan and Bangladesh: contextual differences and opportunities. *Tob Induc Dis* 2021;19:1–17.
- 38 West R, Raw M, McNeill A, et al. Health-Care interventions to promote and assist tobacco cessation: a review of efficacy, effectiveness and affordability for use in national Guideline development. Addiction 2015;110:1388–403.
- 39 Leaviss J, Sullivan W, Ren S, et al. What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation. *Health Technol Assess* 2014;18:1–120.

Detailed methods and results of secondary analyses

Methods

Cytisine dosage schedule

The standard regimen for cytisine (Desmoxan, Aflofarm) was a 25-day course with 1.5mg hard capsules for oral administration, with six per day on days 1-3, five per day on days 4-12, four per day on days 13-16, three per day on days 17-20, two per day on days 21-24 and one on the last day.

Intervention costs

Training for the delivery of brief behavioural support was given to TB health workers before the trial began. In Bangladesh, it was a one-day training programme with a one-day refresher training and the total cost was estimated to be €4499 in 2017. In Pakistan, this consisted of a two-day training programme for DOTS facilitators and the total cost was estimated at €2324 in 2016.

In Bangladesh, the average monthly salary of a TB health worker (local salary grades G-11 to G-13) was PPP US\$649.84, and average working hours per week was 48 hours.¹ In Pakistan, the average monthly salary of a TB health worker was PPP US\$921.50 and average working hours per week was 47.4 hours.² We assumed a 30-day month as 4.3 weeks. The estimated hourly wage was therefore PPP US\$3.17 in Bangladesh and PPP US\$4.54 in Pakistan. The cost of BS was PPP US\$0.52 for the first session and PPP US\$0.26 for the second session in Bangladesh and PPP US\$0.75 and PPP US\$0.38 in Pakistan.

TB treatment costs

The standard treatment for pulmonary TB consisted of a two-month intensive phase and a fourmonth continuation phase. We extracted the overall costs of a six-month TB treatment for the two countries from the World Health Organization (WHO) TB database³ and applied a ratio of costs of the two phases, based on a TB treatment modelling study,⁴ to produce an estimate of monthly cost of intensive phase and continuation phase respectively. They were then converted to PPP US\$.⁵⁶ The TB treatment costs were then estimated based on the participants' treatment progression on their TB registry cards.

Smoking cessation costs outside of the trial

Due to the limited smoking cessation services in the two countries,^{7 8} we made assumptions on duration, based on usual practice in the UK:^{9 10} 10-minute brief intervention with professionals (physician or professional nurse) for help/advice from a public/government clinic/hospital; one hour group session of 15 people or 30-minute individual session led by medical technicians/auxiliary nurses for counselling sessions in public/voluntary hospital. The ratio of group and individual sessions was assumed to be 1:1. The average hourly wage was PPP US\$4.14 for "professionals" and PPP US\$3.33 for "technicians and associate professionals" in Bangladesh, and PPP US\$5.29 for "professionals" and PPP US\$4.51 for "technicians and associate professionals" in Pakistan.¹²⁵

General healthcare services costs

Participants' visits to a public/voluntary doctor and length of stay in a public hospital in the previous six months were collected by self-report at baseline, 6- and 12-month follow-ups. The unit costs of these services were extracted from the WHO country specific in- and out-patient costs, inflated to 2018 and converted to PPP US\$.^{5 11 12} The unit cost of hospital inpatient stay was the average of all hospital levels and the unit cost of a visit to doctor was the average of all settings for outpatient. These costs did not include drugs.

Out-of-pocket payments (OOPs)

Participants' spending related to following items were collected: TB treatment, public/voluntary doctor and hospital visits, and private doctor and hospital visits, including travel, smoking cessation services in public/voluntary facilities and private settings, purchasing Nicotine Replacement Therapy (NRT) or e-cigarette refills, purchasing other traditional medicine for quitting, and purchasing tobacco products.

Results

Costs

Mean training costs were PPP US\$10.94 (SD PPP US\$2.09) per participant in the cytisine arm and PPP US\$10.92 (SD PPP US\$2.09) per participant in the placebo arm. Mean cost of the information leaflet was PPP US\$0.76 (SD PPP US\$0.75) in the cytisine arm and PPP US\$0.75 (SD PPP US\$0.75) in the placebo arm. Mean cost of BS was PPP US\$0.68 (SD PPP US\$0.36) among 1233 participants in the cytisine arm and PPP US\$0.70 (SD US\$0.36) among 1226 participants in the placebo arm. Mean cost of cytisine was PPP US\$48.27 (SD PPP US\$12.54) while the cost of placebo was assumed at zero.

Mean costs of TB treatment were estimated to be PPP US\$307.39 (SD PPP US\$110.25) in the cytisine arm and PPP US\$302.45 (SD PPP US\$108.53) in the placebo arm, excluding 102 (8.2%) participants in the cytisine arm and 103 (8.4%) in the placebo arm who did not have information from TB cards at six-month follow-up (Table 1). The use of smoking cessation support was reported by a small group of participants in both arms. Mean costs of public/voluntary smoking cessation services were low in both arms throughout the 12 months period. Most participants reported neither visiting a doctor other than for their TB treatment nor being admitted to hospital for any reason. While mean costs of doctor visits were similar between respondents in both arms throughout the trial period, mean costs of hospital stay in the cytisine arm were nearly twice as high as in the placebo arm in months 1-6.

Out-of-pocket payments

The respondents reported an increase of spending on smoking cessation in months 1-6 compared to close to none before and after, corresponding with the intervention delivery and TB treatment period. Mean spending on tobacco was lower during the trial period than before among respondents. However, in comparison with the spending on smoking cessation, the spending on tobacco was consistently higher. The OOPs for healthcare services, including travel, loosely followed the same pattern of the costs of the services (Table 1).

	Cytisine (n=1	.239)	Placebo (n=	=1233)			
	n	Mean (SD) PPP US\$	n	Mean (SD) PPP US\$			
TB treatment costs							
TB registry	1137	307.39 (110.25)	1130	302.45 (108.53)			
Additional smoking cessation	costs						
Six months before baseline	1239	0.00 (0.10)	1233	0.00 (0.09)			
Months 1-6	1174	0.47 (1.17)	1164	0.47 (1.11)			
Months 7-12	1134	0.22 (0.75)	1144	0.21 (0.77)			
Doctor visit costs							
Six months before baseline	1239	3.26 (14.27)	1232	3.48 (23.44)			
Months 1-6	1176	3.39 (12.96)	1166	3.04 (10.39)			

Table 1 Mean (SD) costs and OOPs of TB treatment, additional smoking cessation services and general healthcare services, and OOPs on tobacco products, by arm

Months 7-12	1148	1.27 (4.73)	1157	1.12 (4.58)
Hospital stay costs				
Six months before baseline	1237	6.77 (57.79)	1231	4.84 (43.25)
Months 1-6	1175	31.58 (268.99)	1166	16.52 (148.33)
Months 7-12	1148	5.01 (80.30)	1157	5.87 (94.86)
Additional smoking cessation	n OOPs			
Six months before baseline	1236	0.04 (0.75)	1230	0.00 (0.09)
Months 1-6	1091	0.34 (2.72)	1080	0.28 (1.95)
Months 7-12	1110	0.05 (0.61)	1115	0.05 (0.56)
Tobacco OOPs				
Six months before baseline	1229	1.79 (5.05)	1224	1.64 (2.35)
Months 1-6	1177	0.50 (1.03)	1166	0.48 (0.91)
Months 7-12	1148	0.58 (0.92)	1157	0.57 (0.75)
TB treatment OOPs				
Six months before baseline	1238	15.45 (59.42)	1233	19.71 (119.96)
Months 1-6	1174	22.00 (85.28)	1164	15.77 (42.34)
Months 7-12	1148	5.03 (48.72)	1156	4.36 (30.50)
Doctor visit OOPs				<u>.</u>
Six months before baseline	1233	61.53 (243.17)	1227	63.21 (199.10)
Months 1-6	1173	27.49 (238.38)	1158	22.07 (216.35)
Months 7-12	1148	13.28 (84.58)	1157	19.07 (162.71)
Hospital stay OOPs				
Six months before baseline	1237	6.91 (101.21)	1231	3.01 (28.19)
Months 1-6	1173	16.65 (200.58)	1164	11.72 (220.92)
Months 7-12	1148	17.20 (460.84)	1157	5.65 (99.21)

Productivity loss

Among the respondents, while the mean productivity loss peaked in months 1-6 as expected, it was higher than expected in the six months before baseline, most prominently reflected by productivity loss due to participants' sick leave (Table 2). This might correspond with productivity loss due to companion to TB clinic in the six months before baseline, which was consistent with participants' OOPs for TB clinic during the same period.

Table 2 Mean (SD) productivity loss of companion to TB clinic, doctor, and participants' sick leave, by arm

	Cytisine (n=1239)		Placebo	(n=1233)			
	n	Mean (SD) PPP US\$	n	Mean (SD) PPP US\$			
Companion to TB clinic							
Six months before baseline	1232	4.62 (9.01)	1228	4.48 (7.73)			
Month 1 – 6	1134	13.45 (21.55)	1127	12.43 (19.86)			
Month 7 – 12	1145	2.01 (7.40)	1152	2.33 (7.19)			
Companion to doctor							
Six months before baseline	1203	2.10 (9.15)	1196	1.87 (6.05)			
Month 1 – 6	1126	3.35 (13.22)	1116	2.65 (8.44)			
Month 7 – 12	1143	0.37 (2.82)	1151	0.56 (4.82)			
Sick leave							
Six months before baseline	1230	27.14 (73.17)	1227	23.82 (61.12)			
Month 1 – 6	1194	31.98 (100.27)	1171	28.52 (107.49)			

	Cytisine (n=1239)		Placebo (n=1233)	
	n	Mean (SD) PPP US\$	n	Mean (SD) PPP US\$
Month 7 – 12	1163	3.62 (18.24)	1160	5.14 (28.21)

Quality-adjusted life years

In the EQ-5D-5L descriptive system, the domains with least proportion of respondents scoring no problem were Pain/Discomfort and Anxiety/Depression at all three time points although the proportion increased after baseline (Table 3).

Table 3 Number and percentage of respondents scoring five levels of each domain of EQ-5D-5L, by arm and time point

					1						
Domains	Mobility Self-ca		Self-care	e Usual activities		Pain/		Anxiety/			
								Discomfort		Depression	
	Cytisin	Place	Cytisin	Place	Cytisin	Place	Cytisin	Place	Cytisin	Place	
	е	bo	e	bo	е	bo	е	bo	е	bo	
Baseline											
1	731	746	985	993	655	654	413	426	407	411	
	59%	61%	79%	81%	53%	53%	33%	35%	33%	33%	
2	315	291	190	163	380	373	447	462	453	463	
	25%	24%	15%	13%	31%	30%	36%	38%	37%	38%	
3	140	143	49	58	133	146	250	227	232	231	
	11%	12%	4%	5%	11%	12%	20%	18%	19%	19%	
4	50	51	12	16	55	52	114	104	112	98	
	4%	4%	1%	1%	4%	4%	9%	8%	9%	8%	
5	3	2	3	1	14	8	14	13	33	29	
	0%	0%	0%	0%	1%	1%	1%	1%	3%	2%	
Total	1239	1233	1239	1231	1237	1233	1238	1232	1237	1232	
Six months								•			
1	985	992	1077	1078	945	960	753	778	818	829	
	86%	88%	94%	95%	83%	85%	66%	69%	72%	73%	
2	119	116	56	44	171	147	364	325	287	260	
	10%	10%	5%	4%	15%	13%	32%	29%	25%	23%	
3	25	13	7	8	19	18	19	20	28	29	
	2%	1%	1%	1%	2%	2%	2%	2%	2%	3%	
4	12	10	2	2	5	5	6	7	8	12	
	1%	1%	0%	0%	0%	0%	1%	1%	1%	1%	
5	2	1	1	0	3	1	1	1	2	1	
	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	
Total	1143	1132	1143	1132	1143	1131	1143	1131	1143	1131	
12 months											
1	994	1020	1059	1082	968	996	755	780	826	833	
	90%	91%	96%	97%	88%	89%	69%	70%	75%	75%	
2	86	75	33	24	115	101	299	284	226	238	
	8%	7%	3%	2%	10%	9%	27%	26%	21%	21%	
3	11	12	6	2	12	10	35	34	33	28	

	1%	1%	1%	0%	1%	1%	3%	3%	3%	3%
4	8	6	3	4	4	5	9	13	8	13
	1%	1%	0%	0%	0%	0%	1%	1%	1%	1%
5	3	2	1	1	3	1	3	2	4	1
	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Total	1102	1115	1102	1113	1102	1113	1101	1113	1097	1113

Levels for each domain: 1=no problem, 2=slight problem, 3=moderate problem, 4=severe problem, 5=extreme problem/inability

Table 4 shows mean EQ-5D-5L utility and VAS among observed cases at baseline, 6 and 12 months follow-ups and QALYs over 6 and 12 months period. Mean utility in the cytisine arm appeared to be consistently lower than in the placebo arm at all timepoints though the difference was small. The mean QALYs were therefore lower in the cytisine arm than in the placebo arm. However, it should be noted, only those who had data on all relevant timepoints were included in calculating QALYs. The EQ-5D VAS showed a similar pattern where both arms began at similar level but in the cytisine arm, the observed cases scored slightly lower than those in the placebo arm in the follow-ups.

		Cytisine (n=1239)		Placebo (n=1233)
	n	Mean (SD)	n	Mean (SD)
Utility				
Baseline	1234	0.754 (0.133)	1229	0.759 (0.130)
6 months	1179	0.825 (0.165)	1164	0.831 (0.161)
12 months	1144	0.822 (0.189)	1149	0.829 (0.176)
QALYs				
Over 6 months	1174	0.394 (0.056)	1160	0.397 (0.054)
Over 12 months	1129	0.805 (0.134)	1122	0.810 (0.128)
VAS				
Baseline	1239	53.5 (15.4)	1233	53.5 (16.0)
6 months	1179	80.5 (20.3)	1165	81.3 (19.8)
12 months	1150	84.0 (21.8)	1156	84.7 (20.7)

Table 4 Mean (SD) EQ-5D-5L utility, EQ-5D VAS and QALYs, by arm

Cost-utility analysis by country

The mean costs of smoking cessation and healthcare services in the six months before baseline were PPP US\$18.33 (SE PPP US\$3.65) in Pakistan and PPP US\$5.40 (SE PPP US\$1.65) in Bangladesh in the cytisine arm. In the placebo arm, the mean costs of these two types of services were PPP US\$16.35 (SE PPP US\$3.55) in Pakistan and PPP US\$3.72 (SE PPP US\$0.55) in Bangladesh.

The mean costs of intervention were PPP US\$74.37 (SE PPP US\$0.68) in the cytisine arm and PPP US\$15.84 (SE PPP US\$0.03) in the placebo arm in Pakistan. The mean costs of intervention were PPP US\$52.10 (SE PPP US\$0.13) in the cytisine arm and PPP US\$10.23 (SE PPP US\$0.00) in the placebo arm in Bangladesh.

The mean costs of TB treatment in the two arms were on a similar level within each country, over PPP US\$400 in Pakistan and over PPP US\$200 in Bangladesh. The mean costs of doctor visits were very similar between arms in Bangladesh, but they were slightly higher in the cytisine arm in Pakistan (PPP US\$3.17 vs PPP US\$2.66). The most prominent difference was in the mean costs of

hospital stay. In Pakistan, the mean costs of hospital stay were considerably higher in the cytisine arm (PPP US\$78.12 [SE PPP US\$19.80]) than in the placebo arm (PPP US\$32.70 [SE PPP US\$9.76]). On the contrary, in Bangladesh, the mean costs of hospital stay in the placebo arm (PPP US\$7.35 [SE PPP US\$3.82]) were over twice as high as in the cytisine arm (PPP US\$3.07 [SE PPP US\$1.62]). The mean costs of smoking cessation services were not different between arms within each country. However, there were nearly null costs incurred in Pakistan.

Upon further investigation, more participants had hospital stays in Pakistan than in Bangladesh, regardless of which arm they were in. Among participants who incurred hospital stay costs over the six months post-randomisation, not only did the cytisine arm in Pakistan have more participants admitted to hospital but also showed a few potential outliers (Figure 1). This was in contrast with the placebo arm in Pakistan and both arms in Bangladesh.




Figure 1 Distribution of costs of hospital stay among those who incurred this cost, by country and arm

Whilst the mean utility was higher in Pakistan than in Bangladesh, the mean utility in both arms showed a relatively gradual and small increase from baseline to six months (Figure 2). In contrast, the mean utility at baseline was much lower in Bangladesh than in Pakistan but it increased more sharply to a similar level in the cytisine arm and a higher level in the placebo arm.




Figure 2 Mean utility at baseline and six months by country and by arm

Adjusting for costs of healthcare and smoking cessation services in the six months before baseline, age, gender, with sites as random effect, the incremental costs over the six months post randomisation were PPP US\$108.46 (95%CI PPP US\$69.69 to PPP US\$157.88) in Pakistan and PPP US\$37.06 (95% CI PPP US\$28.12 to PPP US\$43.85) in Bangladesh (Table 5). Adjusting for utility at baseline, age, gender, with sites as random effect, the incremental QALYs were 0.001 (95% CI -0.004 to 0.008) in Pakistan and -0.003 (95% CI -0.006 to 0.000) in Bangladesh. Therefore, in Pakistan, the ICER was calculated in at PPP US\$108,464 per QALY and in Bangladesh, the cytisine arm was dominated by the placebo arm (the cytisine arm being more costly but less effective). Figure 3 shows the uncertainty surrounding the ICERs estimated using bootstrap technique. For Bangladesh, 96% (4794/5000) of the bootstrapped replicates fell in the north-west quadrant of the CEP, where the intervention was more costly but less effective in terms of QALYs. This supports the point estimate that the cytisine arm was dominated by the placebo arm. For Pakistan, 71% (3568/5000) of the bootstrapped replicates fell in the north-east quadrant of the CEP, where the intervention was more costly and more effective in terms of QALYs. The rest fell in the north-west quadrant, indicating a more costly but less effective intervention. According to the estimate made by Woods et al., the willingness-to-pay (WTP) threshold for Pakistan was PPP US\$314 to PPP US\$2146 per QALY in 2013 ¹³. Converting to Pakistan Rupees in 2013 then inflating using consumer price index to 2018 ⁵¹⁴, the estimated WTP in Pakistan was PPP US\$356 to PPP US\$2431 per QALY. Represented by the red line in Figure 3, it was apparent that none of the estimates fell under the upper boundary of the WTP (i.e. not cost-effective), same as the point estimate of PPP US\$108,464 per QALY. The probability of the cytisine intervention being cost-effective was 0% throughout a wide range of WTP values in both

countries, the CEACs were therefore not presented. By these results, the cytisine intervention was unlikely to be cost-effective, comparing with placebo, in either Pakistan or Bangladesh.

Table 5 Cost-utility analysis results by country (1 PPPUS\$ = 30.9 Bangladeshi Taka = 29.3 Pakistani Rupees)

Costs (PPP US\$)	Pakistan		Bangladesh		
Mean (SE)	Cytisine (n=476)	Placebo (n=469)	Cytisine (n=763)	Placebo (n=764)	
Intervention	74.37 (0.68)	15.84 (0.03)	52.10 (0.13)	10.23 (0.00)	
TB treatment	421.30 (5.43)	412.97 (5.84)	232.69 (0.78)	233.59 (0.61)	
Doctor visit	3.17 (0.82)	2.66 (0.65)	3.50 (0.29)	3.37 (0.29)	
Hospital stay	78.12 (19.80)	32.70 (9.76)	3.07 (1.62)	7.35 (3.82)	
Smoking	0.00 (0.00)	0.00 (0.00)	0.74 (0.06)	0.71 (0.03)	
cessation					
Overall total for	576.96 (20.65)	464.16 (11.81)	292.07 (1.84)	255.28 (3.88)	
six months					
Adjusted	108.46 (95%CI 69.6	9 to 157.88)	37.06 (95% CI 28.12 to 43.85)		
incremental costs					
QALYs	0.408 (0.002)	0.408 (0.003)	0.387 (0.002)	0.392 (0.002)	
Adjusted	0.001 (95% CI -0.00	4 to 0.008)	-0.003 (95% CI -0.	006 to 0.000)	
incremental					
QALYs					
ICER	108,464 per QALY (uncertainty see	Cytisine dominated by placebo		
	Figure 3)		(uncertainty see F	Figure 3)	




Figure 3 Cost-effectiveness plane of cost-utility analysis results by country

References

- 1. Bangladesh Bureau of Statistics. Report on Labour Force Survey (LFS) 2016-17, 2018.
- 2. Pakistan Bureau of Statistics. Labour Force Survey 2017-18, 2018.
- 3. World Health Organization. Global Tuberculosis report 2018 TB data: WHO, 2018.
- Gomez GB, Dowdy DW, Bastos ML, et al. Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis. *BMC Infect Dis* 2016;16(1):726. doi: 10.1186/s12879-016-2064-3 [published Online First: 2016/12/03]
- 5. The World Bank. DataBank World Development Indicators, 2019.
- 6. International Monetary Fund. National Currency per U.S. Dollar, period average. Inernational Financial Statistics: International Monetary Fund (IMF), 2019.
- 7. World Health Organization. Tobacco control country profile Pakistan. Tobacco control country profiles, 2017.
- 8. World Health Organization. Tobacco control country profile Bangladesh. Tobacco control country profiles, 2017.
- 9. National Institute for Health and Care Excellence. Putting NICE guidance into practice Resource impact report: Stop smoking interventions and services (NG92), 2018.
- 10. Curtis LA, Burns A. Unit Costs of Health and Social Care 2018. Kent: University of Kent, 2018.
- 11. Economic Analysis and Evaluation Team. Country-specific inpatient and outpatient estimates in 2010 currency: World Health Organisation, 2010.
- 12. International Monetary Fund. Prices, Consumer Price Index, All items, Index. International Financial Statistics (IFS): International Monetary Fund (IMF), 2019.
- Woods B, Revill P, Sculpher M, et al. Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research. *Value Health* 2016;19(8):929-35. doi: 10.1016/j.jval.2016.02.017 [published Online First: 2016/12/19]
- 14. International Monetary Fund (IMF). Prices, Consumer Price Index, All items, Index. International Financial Statistics (IFS): International Monetary Fund (IMF), 2019.

_	🛞 TB & Tobacco	CASE REPORT FORM - Visi	t (DAY 0)
			. (

Site ID:	Trial Number:	Date of Completion:		
		Day Month Year		

Section V

ECONOMIC EVALUATION (*This section is about the patient's wider health care use in the past six months, unless stated as TB-specific, this is for any illness.*)

Please exclude care provided by the trial intervention in your answers to these questions.

All costs should be specified in local currency, please round all costs up to the nearest whole number.

Enter a number for each item, if none, enter "0" (zero).

Please use this information to guide you if the patient gives estimates-

For daily visit: One week= 7 days, one month= 30 days, three months= 90 days, six months= 180 days. For weekly visit per month= 4 times.

(i.e "I visited a centre daily for 6 months" would be 180 times)

1.		ou visited a TB clinic in the past six months? exclude current visit and include visits to diagnostic centi	res if separa	ate from clii	nics)
			Yes	🗌 No (go to Q2)
	lf 'Yes	S'			
	a.	How many times have you visited a public/voluntary TB	clinic?		
	b.	How many times have you visited a private TB clinic?			
		In total how much did you pay in the past six months (for consultation, diagnostics, procedures, drugs)? (<i>in local</i>			
	C.	How much did you usually pay for your own travel per v (in local currency)	isit?		
	d.	On how many of these visits were you accompanied by	a friend/rel	ative?	
	e.	How much time in total did it usually take per visit <i>(travel, waiting, procedure)</i> ?	hou	urs	minutes
_	TB & Tobaca	co Day 0 CRF Section 5 (version 2.1 19/07/2017) 11			0380566503

	G TE	B & Tobacco	Trial Number:
2.	-	ou visited a doctor in the past six months (<i>for any illnes</i> ad in Q1)?	s and exclude TB clinic visits
	If 'Ye	s'	
	a.	How many times have you visited a public/voluntary o	loctor?
		In the past six months, in total how much did you pay voluntary visits (for consultation, diagnostics, procedu (in local currency)	
	b.	How many times have you visited a private doctor?	
		In the past six months, in total how much did you pay (for consultation, diagnostics, procedure, drugs)? (in	
	C.	How much time did you usually spend with the doctor	per visit? hours minutes
	d.	How much did you usually pay for your own travel per (in local currency)	visit?
	e.	On how many of these visits were you accompanied b	by a friend/relative etc.?
	f.	How much time in total did it usually take per visit (<i>travel, waiting, procedure</i>)?	hours minutes
3.	Have yo	ou been admitted to hospital in the past six months (<i>for</i>	any illness)?
	a.	How many nights were you in a public/voluntary hosp In total how much did you pay in the past six months hospitals (<i>for consultation, diagnostics, procedures, a</i> <i>stay</i>)? (<i>in local currency</i>)	at public/voluntary
	b.	How many nights were you in a private hospital?	
		In total how much did you pay in the past six months hospitals (for consultation, diagnostics, procedures, or stay)? (in local currency)	
	C.	How much did you usually pay for your own travel per (<i>in local currency</i>)	visit?
	TB & Tobad	cco Day 0 CRF Section 5 (version 2.1 19/07/2017) 12	5443566508

🖓 TB & Tobacco

Trial Number:



4. Have you received any help to stop smoking in the past six months? (please exclude the behavioural support session immediately before joining the trial, the session provided by the trial and any medication provided by the trial)

Yes (go to Q5) No (go to Q6)

5. How many times in the past six months have you *(this question is only about smoking cessation)*: Enter a number for each item, if none enter '0' (zero).

	Number of times	Amount spent out of pocket (in local currency)
Had help or advice about smoking from a public/government clinic/hospital?		
Had help or advice about smoking from a private clinic/hospital?		
Attended a group or single counselling session on smoking at a public/voluntary clinic?		
Attended a group or single counselling session on smoking at a private clinic/hospital?		
Been given a prescription for nicotine patches?		
Been given a prescription for an alternative form of NRT? (such as gum, lozenge, inhaler, etc)		
Bought a refill for an electronic cigarette?		
Been given a prescription for Zyban (Bupropion)?		
Been given a prescription for Champix (Varenicline)?		
Received any traditional medicine?(Hakeem, Homeopathic, Unani etc.)		
Other: please describe:		

9884566501

9.

10.

Γ	ස්ති TB & Tobacco	Trial Number:	
6.	Have you received any medications for TB in the p	east six months?	□ No (go to Q8)

7. Please detail below the medications for TB related illness in the past six months? (Use the colour of the packets to indicate each medication)

(If patient answers not in days: one week= 7 days, one month= 30 days, three months= 90 days, six months= 180 days etc.)

Anti-TB medication	Number of tablets per day	Duration receiving tablets (days)
Fixed-dose combination (4 drugs) (R-150mg/H-75mg/E-275mg/P-400mg)		
Fixed-dose combination (2 drugs) (<i>R-150mg/H-75mg</i>)		

8. Do you have a paid job? (include self-employed and employed) (Please tick one only)

I have a part time job (go to Q9)
I do not have a job (go to Q10)
Have you been off work sick in the past six months <i>(for any illness)</i> ?
No (go to Q10)
If 'Yes' how many days were you off work sick in the last six months?
Usually how much did you spend per day on tobacco over the past six months? (<i>In local currency</i>)

TB & Tobacco Day 0 CRF Section 5 (version 2.1 19/07/2017)

I have a full time job (go to Q9)

9266566505

C TB & Tobacco

Trial Number:



EURO QOL

This section asks about your health in general. Under each heading, please tick the ONE box that best describes your health TODAY.

MOBILITY

I have no problems in walking about

I have slight problems in walking about

I have moderate problems in walking about

I have severe problems in walking about

I am unable to walk about

SELF-CARE

I have no problems washing or dressing myselfI have slight problems washing or dressing myselfI have moderate problems washing or dressing myselfI have severe problems washing or dressing myself

I am unable to wash or dress myself

USUAL ACTIVITIES (e.g. work, study, housework, family or leisure activities)

I have no problems doing my usual activities

I have slight problems doing my usual activities

I have moderate problems doing my usual activities

I have severe problems doing my usual activities

I am unable to do my usual activities

PAIN/DISCOMFORT

I have no pain or discomfort I have slight pain or discomfort I have moderate pain or discomfort I have severe pain or discomfort I have extreme pain or discomfort

ANXIETY/DEPRESSION

I am not anxious or depressed

I am slightly anxious or depressed

I am moderately anxious or depressed

I am severely anxious or depressed

I am extremely anxious or depressed

UK (English) © 2009 EuroQol Group. EQ-5D™ is a trade mark of the EuroQol Group

TB & Tobacco Day 0 CRF Section 5 (version 2.1 19/07/2017)





Γ

TB & Tobacco Trial Numb	ber:
	The best health you can imagine
 We would like to know how good or bad your health is TODAY. The scale is numbered from 0 to 100. 	100 95 90
 100 means the best health you can imagine. 0 means the worst health you can imagine. 	85 80
 Mark an X on the scale to indicate how your health is TODAY. Now, please write the number you marked on the scale in the 	75 70
box below.	65
YOUR HEALTH TODAY =	$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$
UK (English) © 2009 EuroQol Group. EQ-5D™ is a trade mark of the EuroQol Group	The worst health you can imagine

Please dispense medication for 1 week. Instruct the participant to come back for follow up coinciding with their quit date and also to bring the blister packets and the 'dosing schedule card'.

Thank you for your time!

Send data

2624566506

TB & Tobacco Day 0 CRF Section 5 (version 2.1 19/07/2017)

Supplementary tables

Table S1 Average hourly wage by occupation in Pakistan and Bangladesh

	Average hourly wage (PPP US\$) ¹⁻³					
	Banglad	esh		Pakista	an	
Occupation	Male	Female	Total	Male	Female	
Managers	5.68	5.13	5.62	9.67	0.84	
Professionals	4.25	3.93	4.13	6.06	3.84	
Technicians and Associate Professionals	3.35	3.21	3.32	4.69	3.27	
Clerical support workers	2.56	2.33	2.53	4.69	3.16	
Service and Sales workers	1.88	1.76	1.86	2.85	2.37	
Skilled Agricultural, forestry and fisheries	1.50	1.24	1.46	3.03	0.98	
Craft and Related Trades workers	1.69	1.55	1.65	3.00	0.89	
Plant and Machine Operators, and Assembler	1.91	1.77	1.89	2.96	1.95	
Elementary Occupations	1.38	1.15	1.32	2.39	1.11	
Overall	2.14	1.93	2.09	3.35	2.00	

Table S2 Number and proportion of missing values of variables by arm

	Cytisine (n=1239)		Placebo (n=1233)		
Variables	Number of missing values	Proportion of missing values	Number of missing values	Proportion of missing values	
Cost of behavioural support	6	0%	7	1%	
Cost of TB treatment	102	8%	103	8%	
Cost of doctor visit at d0	0	0%	1	0%	
Cost of doctor visit at m6	61	5%	67	5%	
Cost of doctor visit at m12	89	7%	76	6%	
Cost of hospital stay at d0	2	0%	2	0%	
Cost of hospital stay at m6	62	5%	67	5%	
Cost of hospital stay at m12	89	7%	76	6%	
Cost of smoking cessation at d0	0	0%	0	0%	
Cost of smoking cessation at m6	63	5%	69	6%	
Cost of smoking cessation at m12	103	8%	89	7%	
OOP on TB treatment at d0	1	0%	0	0%	
OOP on TB treatment at m6	63	5%	69	6%	
OOP on TB treatment at m12	89	7%	77	6%	
OOP on smoking cessation at d0	3	0%	3	0%	
OOP on smoking cessation at m6	146	12%	153	12%	
OOP on smoking cessation at m12	127	10%	118	10%	
OOP on doctor visit at d0	6	0%	6	0%	
OOP on doctor visit at m6	64	5%	75	6%	
OOP on doctor visit at m12	89	7%	76	6%	
OOP on hospital stay at d0	2	0%	2	0%	
OOP on hospital stay at m6	64	5%	69	6%	
OOP on hospital stay at m12	89	7%	76	6%	
OOP on tobacco products d0	10	1%	9	1%	
OOP on tobacco products m6	60	5%	67	5%	
OOP on tobacco products m12	89	7%	76	6%	
Productivity loss of company for TB treatment at d0	7	1%	5	0%	
Productivity loss of company for TB treatment at m6	103	8%	106	9%	
Productivity loss of company for TB treatment at m12	92	7%	81	7%	
Productivity loss of company for doctor at d0	36	3%	37	3%	
Productivity loss of company for doctor at m6	111	9%	117	9%	
Productivity loss of company for doctor at m12	94	8%	82	7%	
Productivity loss of sick leave at d0	9	1%	6	0%	
Productivity loss of sick leave at m6	44	4%	62	5%	

	Cytisine (n=1239)		Placebo (n=1233)	
Variables	Number of	Proportion	Number of	Proportion
	missing	of missing	missing	of missing
	values	values	values	values
Productivity loss of sick leave at m12	75	6%	73	6%
EQ-5D-5L at d0			1	
1 Mobility	0	0%	0	0%
2 Self-care	0	0%	2	0%
3 Usual activities	2	0%	0	0%
4 Pain and discomfort	1	0%	1	0%
5 Anxiety or depression	2	0%	1	0%
EQ-5D-5L at m6				
1 Mobility	60	5%	67	5%
2 Self-care	60	5%	67	5%
3 Usual activities	60	5%	68	6%
4 Pain and discomfort	60	5%	68	6%
5 Anxiety or depression	60	5%	68	6%
EQ-5D-5L at m12				
1 Mobility	89	7%	76	6%
2 Self-care	89	7%	78	6%
3 Usual activities	89	7%	78	6%
4 Pain and discomfort	90	7%	78	6%
5 Anxiety or depression	94	8%	78	6%
VAS at d0	0	0%	0	0%
VAS at m6	60	5%	68	6%
VAS at m12	89	7%	77	6%
TB score at d0	0	0%	0	0%
TB score at m6	60	5%	66	5%

Missing on:	Allocation	Age	Country
Cost of TB treatment	1.02 (0.76-1.35)	1.02 (1.01-1.03)	0.26 (0.19-0.36)*
Cost of doctor visit at m6	1.07 (0.75-1.53)	1.00 (0.99-1.01)	0.15 (0.10-0.24)*
Cost of doctor visit at m12	0.83 (0.61-1.14)	1.00 (0.99-1.01)	0.17 (0.12-0.25)*
Cost of hospital stay at m6	1.05 (0.74-1.50)	1.00 (0.99-1.01)	0.16 (0.11-0.24)*
Cost of hospital stay at m12	0.83 (0.61-1.14)	1.00 (0.99-1.01)	0.17 (0.12-0.25)*
Cost of smoking cessation at m6	1.07 (0.76-1.52)	1.00 (0.99-1.01)	0.17 (0.11-0.26)*
Cost of smoking cessation at m12	0.84 (0.63-1.13)	1.00 (0.99-1.01)	0.28 (0.21-0.39)*
OOP on TB treatment at m6	1.07 (0.76-1.52)	1.00 (0.99-1.01)	0.16 (0.10-0.24)*
OOP on TB treatment at m12	0.84 (0.62-1.15)	1.00 (0.99-1.01)	0.17 (0.12-0.25)*
OOP on smoking cessation at m6	1.04 (0.82-1.33)	0.99 (0.98-1.00)*	1.14 (0.89-1.47)
OOP on smoking cessation at m12	0.91 (0.70-1.18)	0.99 (0.98-1.00)	0.52 (0.40-0.68)*
OOP on doctor visit at m6	1.15 (0.82-1.62)	1.00 (0.99-1.01)	0.16 (0.10-0.24)*
OOP on doctor visit at m12	0.83 (0.61-1.14)	1.00 (0.99-1.01)	0.17 (0.12-0.25)*
OOP on hospital stay at m6	1.05 (0.74-1.49)	1.00(0.99-1.01)	0.16 (0.11-0.24)*
OOP on hospital stay at m12	0.83 (0.61-1.14)	1.00 (0.99-1.01)	0.17 (0.12-0.25)*
OOP on tobacco products m6	1.09 (0.76-1.55)	1.00 (0.99-1.01)	0.16 (0.10-0.24)*
OOP on tobacco products m12	0.83 (0.61-1.14)	1.00 (0.99-1.01)	0.17 (0.12-0.25)*
Productivity loss of company for TB treatment at m6	1.01 (0.77-1.35)	0.99 (0.98-1.00)	0.55 (0.41-0.73)*
Productivity loss of company for TB treatment at m12	0.86 (0.63-1.16)	1.00 (0.99-1.01)	0.18 (0.13-0.26)*
Productivity loss of company for doctor at m6	1.04 (0.80-1.37)	0.99 (0.98-1.00)	0.52 (0.40-0.69)*
Productivity loss of company for doctor at m12	0.85 (0.63-1.15)	1.00 (0.99-1.01)	0.18 (0.12-0.25)*
Productivity loss of sick leave at m6	1.40 (0.95-2.08)	0.99 (0.97-1.00)	0.22 (0.14-0.33)*
Productivity loss of sick leave at m12	0.95 (0.68-1.32)	0.99 (0.98-1.00)	0.27 (0.19-0.38)*
EQ-5D-5L at m6	1.09 (0.76-1.55)	1.00 (0.99-1.01)	0.16 (0.10-0.24)*
EQ-5D-5L at m12	0.83 (0.61-1.14)	1.00 (0.99-1.01)	0.17 (0.12-0.25)*
TB score at m6	1.02 (0.72-1.44)	1.00 (0.99-1.01)	0.18 (0.12-0.26)*
*P<0.05			

Table S2 Logistic regression for missingness of costs OC	Ps, productivity loss and outcomes on arm and baseline covariates
Tuble 55 Logistic regression for missingness of costs, OC	rs, productivity ioss and outcomes on ann and baseline covariates

*P<0.05

References

- 1. Bangladesh Bureau of Statistics. Report on Labour Force Survey (LFS) 2016-17, 2018.
- 2. Pakistan Bureau of Statistics. Labour Force Survey 2017-18, 2018.
- 3. The World Bank. DataBank World Development Indicators, 2019.